Added to YB: 2026-09-11
Pitch date: 2026-09-09
ARVN [neutral]
Arvinas, Inc.
+0.46%
current return
Author Info
No bio for this author
Company Info
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
Market Cap
$572.8M
Pitch Price
$8.67
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.76
P/E
65.53
EV/Sales
0.04
Sector
Pharmaceuticals
Category
growth
Wells Fargo Biotech Conference Day 1 section 2 - Arvinas, Inc.
ARVN (quick overview): Arvinas is transitioning from a technology company into a clinical-data company, with partner-commercialized vepdegestrant and several approaching readouts. The leading catalyst is year-end Phase 1 data for ARV-393 in lymphoma, though early cohorts were below predicted efficacious exposure and meaningful DLBCL/B-cell data are not expected until 2027. The second major program, ARV-102, is on U.S. clinical hold pending chronic toxicology review, and PSP trial initiation has shifted into 2027.
Read full article (1 min)